Oral glucose tolerance testing to find hidden type 2 diabetes in at-risk people in Guadeloupe
Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe: a Pilot Study
This project will test whether an oral glucose tolerance test (OGTT) finds type 2 diabetes in adults of African or Indian origin in Guadeloupe who have normal fasting blood glucose but diabetes risk factors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 1 site (Pointe-à-Pitre, Guadeloupe) |
| Trial ID | NCT07233434 on ClinicalTrials.gov |
What this trial studies
Because fasting blood glucose (FBG) alone may miss diabetes in people of Afro‑Caribbean and Indo‑Caribbean descent, this project uses OGTT to screen adults with normal FBG but risk factors and HbA1c 5.7–6.4%. Eligible participants (ages 18–65) will have an OGTT at the hospital and a 2‑hour glucose ≥11 mmol/L (200 mg/dL) will confirm diabetes. Diagnosed participants will be treated according to national recommendations and monitored over one year, while those with normal OGTT will repeat testing at 12 months. The study aims to estimate how many additional diabetes cases OGTT detects compared with FBG in this specific population.
Who should consider this trial
Good fit: Adults 18–65 in Guadeloupe who self-identify as of African or Indian origin, have normal fasting blood glucose but HbA1c 5.7–6.4% and at least one risk factor (BMI >25, family history, hypertension, or dyslipidemia), and can give informed consent.
Not a fit: People without the listed risk factors, those outside the 18–65 age range, non–African/Indian origin, pregnant or with conditions or medications that affect glucose metabolism, or those already diagnosed with diabetes are unlikely to benefit from this screening approach.
Why it matters
Potential benefit: If successful, OGTT could identify people with undiagnosed type 2 diabetes earlier so they can start treatment and monitoring sooner.
How similar studies have performed: Other international guidelines include OGTT and prior research shows OGTT can detect additional diabetes cases missed by fasting glucose, though targeted data in Afro‑Caribbean and Indo‑Caribbean populations are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
o Inclusion criteria : Adult subject (over 18 years and under 65 years old) Subjects of African or Indian origin and self-declared Normal FBG levels (110mg/dL) HbA1c levels between 5.7 and 6.4% One or more of the following factors: BMI \> 25 kg/m2, family history of T2DM in the 1st and 2nd familial degree, hypertension, dyslipidemia. Affiliation to the national social health system or equivalent Informed and written consent signed by the patient and the investigator (at the latest on the day of inclusion and before the completion of any research related exam) o Exclusion criteria : Pregnant or lactating woman Women with a history of gestational diabetes Polycystic ovary syndrome Endocrine, hepatic or renal diseases affecting glycemic control Treatment that affect the metabolism of glucose or insulin Refusal to participate Subjects without adequate or impaired decisional abilities for consent to research and placed under guardianship, curatorship or safeguard of justice, person participating in another research including an exclusion period still in progress, severely impaired physical and / or psychological health, which, according to the investigator, may affect the compliance of the study participant
Where this trial is running
Pointe-à-Pitre, Guadeloupe
- Centre Hospitalier Universitaire de la Guadeloupe — Pointe-à-Pitre, Guadeloupe, Guadeloupe (Recruiting)
Study contacts
- Principal investigator: Fritz-Line VELAYOUDOM, Doctor — CHU de la Guadeloupe
- Study coordinator: Valérie HAMONY-SOTER
- Email: valerie.soter@chu-guadeloupe.fr
- Phone: +590 590 93 46 77
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.